This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 1993 Dec;32(6):792-6.

doi: 10.1093/jac/32.6.792.

Dosage recommendations for teicoplanin

A P Wilson¹, R N Grüneberg, H Neu

Affiliations

PMID: 8144419
DOI: 10.1093/jac/32.6.792

Review

Dosage recommendations for teicoplanin

A P Wilson et al. J Antimicrob Chemother. 1993 Dec.

. 1993 Dec;32(6):792-6.

doi: 10.1093/jac/32.6.792.

Authors

A P Wilson¹, R N Grüneberg, H Neu

Affiliation

¹ Department of Clinical Microbiology, University College Hospital, London, UK.

PMID: 8144419
DOI: 10.1093/jac/32.6.792

No abstract available

PubMed Disclaimer

Similar articles

Clinical evaluation of teicoplanin in the treatment of gram-positive bacterial intravascular infections.
Livornese LL, Gold M, Johnson CC, Measley R, Kaye D, Korzeniowski O, Walsh ML, Samel C, Hessen M, Levison ME. Livornese LL, et al. J Antimicrob Chemother. 1993 Jan;31(1):188-91. doi: 10.1093/jac/31.1.188. J Antimicrob Chemother. 1993. PMID: 8444670 No abstract available.
Treatment of cerebrospinal fluid shunt infections with teicoplanin.
Fernández Guerrero ML, de Górgolas M, Fernández Roblas R, Campos JM. Fernández Guerrero ML, et al. Eur J Clin Microbiol Infect Dis. 1994 Dec;13(12):1056-8. doi: 10.1007/BF02111827. Eur J Clin Microbiol Infect Dis. 1994. PMID: 7889968
Evaluation of teicoplanin's therapeutic efficacy in immunocompromised patients with staphylococcal sepsis.
Orani A, Fossati M, Castelli N, Sala A. Orani A, et al. J Chemother. 1989 Jul;1(4 Suppl):716-9. J Chemother. 1989. PMID: 16312605 No abstract available.
[Emergence of gram-positive organisms: causes, clinical significance and possibilities of control].
García-Rodríguez JA, García Sánchez E. García-Rodríguez JA, et al. Rev Clin Esp. 1997 Sep;197 Suppl 2:3-11. Rev Clin Esp. 1997. PMID: 9441320 Review. Spanish. No abstract available.
[Streptogramins and glycopeptides].
Tsuji A. Tsuji A. Nihon Rinsho. 2007 Feb 28;65 Suppl 2 Pt. 1:360-6. Nihon Rinsho. 2007. PMID: 17455646 Review. Japanese. No abstract available.

See all similar articles

Cited by

Therapeutic drug concentrations of teicoplanin in clinical settings.
Nah SY, Im JH, Yeo JY, Baek JH, Kim CW, Nam MS, Lee HK, Chung MH, Lee JS. Nah SY, et al. Infect Chemother. 2014 Mar;46(1):35-41. doi: 10.3947/ic.2014.46.1.35. Epub 2014 Mar 21. Infect Chemother. 2014. PMID: 24693468 Free PMC article.
Use of teicoplanin in community medicine.
Wilson AP, Grüneberg RN. Wilson AP, et al. Eur J Clin Microbiol Infect Dis. 1994 Sep;13(9):701-10. doi: 10.1007/BF02276052. Eur J Clin Microbiol Infect Dis. 1994. PMID: 7843174 Review.
Efficacy of vancomycin and teicoplanin alone and in combination with streptomycin in experimental, low-level vancomycin-resistant, VanB-type Enterococcus faecalis endocarditis.
Nicolau DP, Marangos MN, Nightingale CH, Patel KB, Cooper BW, Quintiliani R Jr, Courvalin P, Quintiliani R. Nicolau DP, et al. Antimicrob Agents Chemother. 1996 Jan;40(1):55-60. doi: 10.1128/AAC.40.1.55. Antimicrob Agents Chemother. 1996. PMID: 8787879 Free PMC article.
Anti-infective treatment in intensive care: the role of glycopeptides.
Grüneberg RN, Wilson AP. Grüneberg RN, et al. Intensive Care Med. 1994 Nov;20 Suppl 4:S17-22. doi: 10.1007/BF01713978. Intensive Care Med. 1994. PMID: 7699151 Review.
A risk-benefit assessment of teicoplanin in the treatment of infections.
de Lalla F, Tramarin A. de Lalla F, et al. Drug Saf. 1995 Nov;13(5):317-28. doi: 10.2165/00002018-199513050-00005. Drug Saf. 1995. PMID: 8785019 Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Silverchair Information Systems
Medical
- ClinicalTrials.gov